A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical SettingAn Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 DiabetesA Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy VolunteersA Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy VolunteersA Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy VolunteersA Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy VolunteersEffect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy VolunteersA Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes MellitusA Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusA Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy VolunteersA Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR TabletThe Effect of Food on the Administration of Canagliflozin in Healthy Adult VolunteersA Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy VolunteersAn Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin MonotherapyA Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy VolunteersMetformin And Cardiovascular Effectiveness vs SGLT2 (MACES)Glucose Absorption and Gut Hormone Secretion After Gastric BypassPerformance Under SGLT-2-Inhibitors in HumansReplication of the CANVAS Diabetes Trial in Healthcare ClaimsA Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants (2014-02-28)A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components (2014-02-28)A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus (2007-06-30)A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart FailureA Study of Canagliflozin + Metformin Hydrochloride Immediate Release (IR) Fixed-Dose Combination as an Adjunct to Diet and Exercise to Improve Glycemic Control in Indian Adult Participants With Type 2 Diabetes Mellitus
P4844
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsIpragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trialCanagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentStereoselective C-glycosylation reactions with arylzinc reagentsCanagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsEffect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 studyDual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations
P921
Q61907421-27E1CBFA-5562-446F-9C30-C8D8E69CE1D0Q61914745-9D395C69-669C-4F94-BC56-77DDE76829CBQ61956616-F49BAF66-8A0E-4D88-AA2D-864DEE0ACB76Q61956618-675EC23F-1B33-4B0E-9584-AD4C1FCA8CD9Q61956857-8BAADD75-B473-42CF-BC9B-4B7DC0A9A1EBQ61956949-FE67439B-8FCC-49E0-B30E-EF89AD3DEFAAQ61965816-937D46D3-7707-45D6-9250-E9DC26E5CD4FQ61969270-32DE49E9-5F5F-4D21-86FF-D564EBB1D1ECQ61970149-A2E97300-3FF4-480E-AFAF-9D82EAFC3CF3Q63320657-B248A521-7048-4CC2-B22C-05E940C5EB69Q63321349-0B9AE782-F557-4ED9-B484-D51F9750F84AQ63337206-0E0FD6E1-54AD-4E94-ADAB-71FFD307AAD1Q63338162-48449E91-6828-44F8-A8F0-AB2AF6E05EADQ63338166-0B25A2A7-8429-41C3-B03E-B5ACE7392149Q63339363-8F481339-F499-4F00-AC21-13741933EEA8Q63394470-F739D3B6-5C11-4F3E-A53C-F6830C9CCF2AQ63401352-45879C8C-82DD-4F36-8329-5374A037C689Q63402926-E0545F15-5A6D-439E-9E01-FD6B1D0431E4Q63805253-D05BFC6D-91FF-457E-854F-1EB44A995B25Q86166023-1704F6DB-5D13-45C2-9A3A-194897F6BB7DQ86166090-9B293BED-60E8-49A9-B694-DC138F1057E6Q86172998-DEA3AD17-0175-433B-BD42-2EC0A5EC3AB8Q86294756-6B878542-EB9B-4A8C-AF9A-D6545CE669E9Q87079041-2E86307B-2B17-46B1-A231-FA7917401378
P4844
Q28732080-EF2FC8B5-9B36-43D7-A758-C1AB1F30421BQ30612949-7A0230F9-6184-4076-9C09-2D11BA7E2FC0Q34227891-3E0B2D26-92BE-4BC5-9411-E73A9560AD38Q34453811-043B4823-DD18-4C87-841A-C8615C85F4D0Q34646948-572DACD1-4FFC-4FA3-941A-A912EDC359ECQ34647844-EAC6023E-E03E-418E-96E3-79229536061BQ36845771-FE51C5F0-F053-46B4-8A60-E8EE5FDBADBFQ36997767-9476BF7E-5AFD-4AA7-AA4A-EA2013185BF9Q37022726-B98A608E-8F59-4103-B8D7-CCD312204D14Q37106527-F0324193-8814-48EA-A155-E63B51A9B0CEQ38099395-12A84226-1055-46E0-BC96-80D75F02114AQ42944430-37B45BA3-27BA-48D0-B239-81EB3AA8EF3CQ51337136-EF27CA4C-46D2-4EF6-B11C-A9B0886F39FFQ51362851-7955D817-557C-421A-AAA8-85F8CB360C12Q61955764-D5A6304D-A873-4848-96B0-C487E8A35E93Q83560606-0F00BDA1-DE4D-452A-BBF8-09B077EE2797Q83764954-686D6A5A-759F-494C-888E-CC1DEC463ACBQ84047593-F19C04D9-8960-4E7A-AD07-4C0085B3632AQ84201941-5333DEEA-9FA2-49B9-BC2C-2A7A7AC62261
P921
description
Antidiabetikum
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Canagliflozin
@de
Canagliflozin
@it
Canagliflozin
@nl
Canagliflozin
@vi
Canagliflozina
@es
Kanagliflozin
@sh
Kanagliflozin
@sr
canagliflozin
@en
canagliflozin
@fr
كاناجليفلوزين
@ar
type
label
Canagliflozin
@de
Canagliflozin
@it
Canagliflozin
@nl
Canagliflozin
@vi
Canagliflozina
@es
Kanagliflozin
@sh
Kanagliflozin
@sr
canagliflozin
@en
canagliflozin
@fr
كاناجليفلوزين
@ar
altLabel
1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene
@en
Canagliflozin anhydrous
@en
Canagliflozin
@en
JNJ-28431754
@en
TA-7284
@en
canagliflozin anhydrous
@en
prefLabel
Canagliflozin
@de
Canagliflozin
@it
Canagliflozin
@nl
Canagliflozin
@vi
Canagliflozina
@es
Kanagliflozin
@sh
Kanagliflozin
@sr
canagliflozin
@en
canagliflozin
@fr
كاناجليفلوزين
@ar
P486
P592
P6366
P661
P662
P665
P683
P1579
P2017
CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F